Drugs / OnabotulinumtoxinA X
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05152576 | Nov 2021 → Sep 2022 | — | Allergan | Completed | Met primary |
| Phase 2 | NCT05100199 | Oct 2021 → Dec 2022 | — | Allergan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OnabotulinumtoxinA X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05100199 ↗ |
| Modality | Protein / enzyme biologic | “small quantities of botulinum toxin” NCT05152576 ↗ |
| Route | Intramuscular | “Intramuscular Injection” NCT05152576 ↗ |